A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less than two weeks to conduct due diligence. The client retained Alacrita to conduct a focused due diligence covering the clinical strategy and data, regulatory issues, CMC issues and the commercial opportunity.
Alacrita assembled a team comprising an former Chief Medical Officer who had previously designed and managed many oncology trials ranging from translational through to Phase 3; a CMC expert with over 20 years experience in biologics manufacturing; and a former executive who had recently designed a launch plan in the same indication and was therefore able to conduct a rapid assessment of commercial prospects. The due diligence revealed several major issues which together increased the risk level to higher than would be normally be expected at this stage of product development.
Due Diligence Services
Alacrita's due diligence experts have conducted over 200 major assignments for large pharma, biotech, universities and investors, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise expertise required for a complete, thorough and accurate assessment.Back